Meta-analysis of endoscopic therapy for low-grade dysplasia in Barrett's oesophagus

British Journal of Surgery

Volumn 101, Issue 10, 2014, Pages 1187-1195

  Almond, L M ^a   Hodson, J ^b   Barr, H ^a  

^a GLOUCESTERSHIRE ROYAL HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BARRETT ESOPHAGUS; DISEASE COURSE; ESOPHAGOSCOPY; ESOPHAGUS TUMOR; HUMAN; META ANALYSIS; PATHOLOGY; POSTOPERATIVE COMPLICATION; PRECANCER; REVIEW; TREATMENT OUTCOME;

BARRETT ESOPHAGUS; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; ESOPHAGOSCOPY; HUMANS; POSTOPERATIVE COMPLICATIONS; PRECANCEROUS CONDITIONS; TREATMENT OUTCOME;

EID: 84905905710     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.9573     Document Type: Review

References (49)

1. Vaezi MF, Richter JE,. Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. Gastroenterology 1996; 111: 1192-1199.
2. Dvorak K, Payne CM, Chavarria M, Ramsey L, Dvorakova B, Bernstein H, et al. Bile acids in combination with low pH induce oxidative stress and oxidative DNA damage: relevance to the pathogenesis of Barrett's oesophagus. Gut 2007; 56: 763-771.
3. Phoa KN, van Vilsteren FG, Weusten BL, Bisschops R, Schoon EJ, Ragunath K, et al. Radiofrequency ablation vs endoscopic surveillance for patients with low-grade dysplasia: a randomized clinical trial. JAMA 2014; 311: 1209-1217.
4. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
5. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-analyses. http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp [accessed 1 June 2013].
6. Dahabreh IJ, Trikalinos TA, Lau J, Schmid C,. An Empirical Assessment of Bivariate Methods for Meta-Analysis of Test Accuracy. Agency for Healthcare Research and Quality. http://www.ncbi.nlm.nih.gov/books/NBK115736/ [accessed 1 November 2012].
7. Byrne JP, Armstrong GR, Attwood SE,. Restoration of the normal squamous lining in Barrett's esophagus by argon beam plasma coagulation. Am J Gastroenterol 1998; 93: 1810-1815.
8. Van Laethem JL, Cremer M, Peny MO, Delhaye M, Devière J,. Eradication of Barrett's mucosa with argon plasma coagulation and acid suppression: immediate and mid term results. Gut 1998; 43: 747-751.
9. Gossner L, May A, Stolte M, Seitz G, Hahn EG, Ell C,. KTP laser destruction of dysplasia and early cancer in columnar-lined Barrett's esophagus. Gastrointest Endosc 1999; 49: 8-12.
10. Overholt BF, Panjehpour M, Haydek JM,. Photodynamic therapy for Barrett's esophagus: follow-up in 100 patients. Gastrointest Endosc 1999; 49: 1-7.
11. Pereira-Lima JC, Busnello JV, Saul C, Toneloto EB, Lopes CV, Rynkowski CB, et al. High power setting argon plasma coagulation for the eradication of Barrett's esophagus. Am J Gastroenterol 2000; 95: 1661-1668.
12. Wani S, Puli SR, Shaheen NJ, Westhoff B, Slehria S, Bansal A, et al. Esophageal adenocarcinoma in Barrett's esophagus after endoscopic ablative therapy: a meta-analysis and systematic review. Am J Gastroenterol 2009; 104: 502-513.
13. Morris CD, Byrne JP, Armstrong GR, Attwood SE,. Prevention of the neoplastic progression of Barrett's oesophagus by endoscopic argon beam plasma ablation. Br J Surg 2001; 88: 1357-1362.
14. Zöpf T, Rosenbaum A, Apel D, Jakobs R, Arnold JC, Riemann JF. [Photodynamic therapy of dysplasias and early carcinomas in Barrett esophagus with a diode laser system-a pilot study.] Med Klin (Munich) 2001; 96: 212-216.
15. Kahaleh M, Van Laethem JL, Nagy N, Cremer M, Devière J,. Long-term follow-up and factors predictive of recurrence in Barrett's esophagus treated by argon plasma coagulation and acid suppression. Endoscopy 2002; 34: 950-955.
16. Ortner MA, Dorta G, Blum AL, Michetti P,. Endoscopic interventions for preneoplastic and neoplastic lesions: mucosectomy, argon plasma coagulation, and photodynamic therapy. Dig Dis 2002; 20: 167-172.
17. Morino M, Rebecchi F, Giaccone C, Taraglio S, Sidoli L, Ferraris R,. Endoscopic ablation of Barrett's esophagus using argon plasma coagulation (APC) following surgical laparoscopic fundoplication. Surg Endosc 2003; 17: 539-542.
18. Overholt BF, Panjehpour M, Halberg DL,. Photodynamic therapy for Barrett's esophagus with dysplasia and/or early stage carcinoma: long-term results. Gastrointest Endosc 2003; 58: 183-188.
19. Familiari L, Scaffidi M, Bonica M, Consolo P, Giacobbe G, Fichera D, et al. Endoscopic treatment of Barrett's epithelium with argon plasma coagulation. Long-term follow-up. Minerva Gastroenterol Dietol 2003; 49: 63-70.
20. Ackroyd R, Kelty CJ, Brown NJ, Stephenson TJ, Stoddard CJ, Reed MW,. Eradication of dysplastic Barrett's oesophagus using photodynamic therapy: long-term follow-up. Endoscopy 2003; 35: 496-501.
21. Hage M, Siersema PD, van Dekken H, Steyerberg EW, Haringsma J, van de Vrie W, et al. 5-Aminolevulinic acid photodynamic therapy versus argon plasma coagulation for ablation of Barrett's oesophagus: a randomised trial. Gut 2004; 53: 785-790.
22. Dulai GS, Jensen DM, Cortina G, Fontana L, Ippoliti A,. Randomized trial of argon plasma coagulation versus multipolar electrocoagulation for ablation of Barrett's esophagus. Gastrointest Endosc 2005; 61: 232-240.
23. Ragunath K, Krasner N, Raman VS, Haqqani MT, Phillips CJ, Cheung I,. Endoscopic ablation of dysplastic Barrett's oesophagus comparing argon plasma coagulation and photodynamic therapy: a randomized prospective trial assessing efficacy and cost-effectiveness. Scand J Gastroenterol 2005; 40: 750-758.
24. Bright T, Watson DI, Tam W, Game PA, Astill D, Ackroyd R, et al. Randomized trial of argon plasma coagulation versus endoscopic surveillance for Barrett esophagus after antireflux surgery: late results. Ann Surg 2007; 246: 1016-1020.
25. Mörk H, Al-Taie O, Berlin F, Kraus MR, Scheurlen M,. High recurrence rate of Barrett's epithelium during long-term follow-up after argon plasma coagulation. Scand J Gastroenterol 2007; 42: 23-27.
26. Roorda AK, Marcus SN, Triadafilopoulos G,. Early experience with radiofrequency energy ablation therapy for Barrett's esophagus with and without dysplasia. Dis Esophagus 2007; 20: 516-522.
27. Hernandez JC, Reicher S, Chung D, Pham BV, Tsai F, Disibio G, et al. Pilot series of radiofrequency ablation of Barrett's esophagus with or without neoplasia. Endoscopy 2008; 40: 388-392.
28. Sharma VK, Jae Kim H, Das A, Wells CD, Nguyen CC, Fleischer DE,. Circumferential and focal ablation of Barrett's esophagus containing dysplasia. Am J Gastroenterol 2009; 104: 310-317.
29. Eldaif SM, Lin E, Singh KA, Force SD, Miller DL,. Radiofrequency ablation of Barrett's esophagus: short-term results. Ann Thorac Surg 2009; 87: 405-410.
30. Pouw RE, Wirths K, Eisendrath P, Sondermeijer CM, Ten Kate FJ, Fockens P, et al. Efficacy of radiofrequency ablation combined with endoscopic resection for Barrett's esophagus with early neoplasia. Clin Gastroenterol Hepatol 2010; 8: 23-29.
31. Lyday WD, Corbett FS, Kuperman DA, Kalvaria I, Mavrelis PG, Shughoury AB, et al. Radiofrequency ablation of Barrett's esophagus: outcomes of 429 patients from a multicenter community practice registry. Endoscopy 2010; 42: 272-278.
32. Vassiliou MC, von Renteln D, Wiener DC, Gordon SR, Rothstein RI,. Treatment of ultralong-segment Barrett's using focal and balloon-based radiofrequency ablation. Surg Endosc 2010; 24: 786-791.
33. dos Santos RS, Bizekis C, Ebright M, DeSimone M, Daly BD, Fernando HC,. Radiofrequency ablation for Barrett's esophagus and low-grade dysplasia in combination with an antireflux procedure: a new paradigm. J Thorac Cardiovasc Surg 2010; 139: 713-716.
34. Shaheen NJ, Overholt BF, Sampliner RE, Wolfsen HC, Wang KK, Fleischer DE, et al. Durability of radiofrequency ablation in Barrett's esophagus with dysplasia. Gastroenterology 2011; 141: 460-468.
35. Polese L, Angriman I, Scarpa M, Pagano D, Parente P, Erroi F, et al. Diode laser treatment of Barrett's esophagus: long-term results. Lasers Med Sci 2011; 26: 223-228.
36. Alvarez Herrero L, van Vilsteren FG, Pouw RE, ten Kate FJ, Visser M, Seldenrijk CA, et al. Endoscopic radiofrequency ablation combined with endoscopic resection for early neoplasia in Barrett's esophagus longer than 10 cm. Gastrointest Endosc 2011; 73: 682-690.
37. Caillol F, Bories E, Pesenti C, Poizat F, Monges G, Guiramand J, et al. Radiofrequency ablation associated to mucosal resection in the oesophagus: experience in a single centre. Clin Res Hepatol Gastroenterol 2012; 36: 371-377.
38. Zemlyak AY, Pacicco T, Mahmud EM, Tsirline VB, Belyansky I, Walters A, et al. Radiofrequency ablation offers a reliable surgical modality for the treatment of Barrett's esophagus with a minimal learning curve. Am Surg 2012; 78: 774-778.
39. Haidry RJ, Dunn J, Banks M, Gupta A, Butt MA, Smart H, et al. HALO radiofrequency ablation for high grade dysplasia and early mucosal neoplasia arising in Barrett's oesophagus: interim results from the UK HALO radiofrequency ablation registry. Gastroenterology 2012; 142 (Suppl 1): 745.
40. Orman ES, Kim HP, Bulsiewicz WJ, Cotton CC, Dellon ES, Spacek MB, et al. Intestinal metaplasia recurs infrequently in patients successfully treated for Barrett's esophagus with radiofrequency ablation. Am J Gastroenterol 2013; 108: 187-195.
41. Shaheen NJ, Sharma P, Overholt BF, Wolfsen HC, Sampliner RE, Wang KK, et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med 2009; 360: 2277-2288.
42. Hvid-Jensen F, Pedersen L, Drewes AM, Sørensen HT, Funch-Jensen P,. Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med 2011; 365: 1375-1383.
43. Bhat S, Coleman HG, Yousef F, Johnston BT, McManus DT, Gavin AT, et al. Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. J Natl Cancer Inst 2011; 103: 1049-1057.
44. Wani S, Falk GW, Post J, Yerian L, Hall M, Wang A, et al. Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus. Gastroenterology 2011; 141: 1179-1186, 1186.e1.
45. de Jonge PJ, van Blankenstein M, Looman CW, Casparie MK, Meijer GA, Kuipers EJ,. Risk of malignant progression in patients with Barrett's oesophagus: a Dutch nationwide cohort study. Gut 2010; 59: 1030-1036.
46. Almond LM, Barr H, Jankowski J,. Barrett's oesophagus. In A Companion to Specialist Surgical Practice: Oesophagogastric Surgery (5th edn), Griffin SM, Raimes SA, Shenfine J (eds). Saunders Elsevier: London, 2014; 280-297.
47. Curvers WL, ten Kate FJ, Krishnadath KK, Visser M, Elzer B, Baak LC, et al. Low-grade dysplasia in Barrett's esophagus: overdiagnosed and underestimated. Am J Gastroenterol 2010; 105: 1523-1530.
48. Bird-Lieberman EL, Dunn JM, Coleman HG, Lao-Sirieix P, Oukrif D, Moore CE, et al. Population-based study reveals new risk-stratification biomarker panel for Barrett's esophagus. Gastroenterology 2012; 143: 927-935.e3.
49. Alvi MA, Liu X, O'Donovan M, Newton R, Wernisch L, Shannon NB, et al. DNA methylation as an adjunct to histopathology to detect prevalent, inconspicuous dysplasia and early-stage neoplasia in Barrett's esophagus. Clin Cancer Res 2013; 19: 878-888.